

Larissa Haertle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4276298/publications.pdf>

Version: 2024-02-01

13
papers

249
citations

1162367

8
h-index

1372195

10
g-index

13
all docs

13
docs citations

13
times ranked

592
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic signatures of gestational diabetes mellitus on cord blood methylation. <i>Clinical Epigenetics</i> , 2017, 9, 28.	1.8	85
2	IKZF1/3 and CRL4 ^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , 2020, 105, e237-e241.	1.7	41
3	Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. <i>Blood Advances</i> , 2021, 5, 3794-3798.	2.5	30
4	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
5	Allele-specific methylation of imprinted genes in fetal cord blood is influenced by cis-acting genetic variants and parental factors. <i>Epigenomics</i> , 2018, 10, 1315-1326.	1.0	20
6	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. <i>Communications Biology</i> , 2021, 4, 799.	2.0	16
7	Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients. <i>International Journal of Cancer</i> , 2018, 143, 1416-1425.	2.3	15
8	Hypermethylation of the non-imprinted maternal MEC3 and paternal MEST alleles is highly variable among normal individuals. <i>PLoS ONE</i> , 2017, 12, e0184030.	1.1	12
9	Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4349-4349.	0.6	4
10	RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1277-1277.	0.6	1
11	Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation. <i>Blood</i> , 2018, 132, 404-404.	0.6	0
12	Clonal Competition Models to Understand Progression and Resistance in Myeloma. <i>Blood</i> , 2019, 134, 1807-1807.	0.6	0
13	High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β 2 Subunit of Proteasome Complex: The First in Human Evidence. <i>Blood</i> , 2021, 138, 818-818.	0.6	0